These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17373639)

  • 1. Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure.
    Berthe E; Lireux B; Coffin C; Goulet-Salmon B; Houlbert D; Boutreux S; Fradin S; Reznik Y
    Horm Metab Res; 2007 Mar; 39(3):224-9. PubMed ID: 17373639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes.
    Hanaire-Broutin H; Melki V; Bessières-Lacombe S; Tauber JP
    Diabetes Care; 2000 Sep; 23(9):1232-5. PubMed ID: 10977011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
    Ruiz-de-Adana MS; Dominguez-Lopez ME; Gonzalez-Molero I; Machado A; Martin V; Cardona I; de-la-Higuera M; Tapia MJ; Soriguer F; Anarte MT; Rojo-Martínez G
    Med Clin (Barc); 2016 Mar; 146(6):239-46. PubMed ID: 26656958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system.
    Bode BW; Steed RD; Schleusener DS; Strange P
    Endocr Pract; 2005; 11(3):157-64. PubMed ID: 16239201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes.
    Sargin H; Sargin M; Altuntaş Y; Sengül AM; Orbay E; Seber S; Uçak S; Yayla A
    Diabetes Res Clin Pract; 2003 Nov; 62(2):79-86. PubMed ID: 14581144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.
    Roach P; Bai S; Charbonnel B; Consoli A; Taboga C; Tiengo A; Bolli G;
    Clin Ther; 2004 Apr; 26(4):502-10. PubMed ID: 15189747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections.
    Colombel A; Murat A; Krempf M; Kuchly-Anton B; Charbonnel B
    Diabet Med; 1999 Apr; 16(4):319-24. PubMed ID: 10220206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial.
    Aronson R; Reznik Y; Conget I; Castañeda JA; Runzis S; Lee SW; Cohen O;
    Diabetes Obes Metab; 2016 May; 18(5):500-7. PubMed ID: 26854123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
    Pala L; Dicembrini I; Mannucci E
    Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial.
    Reznik Y; Cohen O; Aronson R; Conget I; Runzis S; Castaneda J; Lee SW;
    Lancet; 2014 Oct; 384(9950):1265-72. PubMed ID: 24998009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide.
    Roach ; Koledova E; Metcalfe S; Hultman C; Milicevic Z;
    Clin Ther; 2001 Oct; 23(10):1732-44. PubMed ID: 11726007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lispro is superior to regular insulin in transient intensive insulin therapy in type 2 diabetes.
    Murase Y; Yagi K; Sugihara M; Chujo D; Otsuji M; Muramoto H; Mabuchi H
    Intern Med; 2004 Sep; 43(9):779-86. PubMed ID: 15497510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure.
    Altuntas Y; Ozen B; Ozturk B; Sengul A; Ucak S; Ersoy O; Karul S
    Diabetes Obes Metab; 2003 Nov; 5(6):371-8. PubMed ID: 14617222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.
    Renner R; Pfützner A; Trautmann M; Harzer O; Sauter K; Landgraf R
    Diabetes Care; 1999 May; 22(5):784-8. PubMed ID: 10332682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment.
    Lepore G; Dodesini AR; Nosari I; Trevisan R
    Diabetes Care; 2003 Apr; 26(4):1321-2. PubMed ID: 12663625
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen.
    Cappelleri JC; Cefalu WT; Rosenstock J; Kourides IA; Gerber RA
    Clin Ther; 2002 Apr; 24(4):552-64. PubMed ID: 12017400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
    Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
    Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.